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Abstract
Background & Aims—Data regarding the risk of gastrointestinal and extra-intestinal cancers in 
Crohn’s disease (CD) and ulcerative colitis (UC) are needed to understand the clinical course of 
inflammatory bowel diseases (IBDs) and their treatments.
Methods—We performed a nationwide historical cohort study using Danish healthcare 
databases. We identified patients with a diagnosis of CD or UC, recorded from 1978 through 
2010, and followed them until first occurrence of cancer, death, or emigration. We used 
standardized incidence ratios (SIRs) to compare cancer incidence in CD and UC patients to that 
expected in the general population.
Results—Excluding cancers diagnosed within 1 year of IBD diagnosis, 772 cases of invasive 
cancer occurred among 13,756 patients with CD (SIR, 1.3; 95% confidence interval [CI], 1.2–1.4) 
and 2331 occurred among 35,152 patients with UC (SIR, 1.1; 95% CI, 1.0–1.1). CD was weakly 
associated with gastrointestinal cancers (SIR 1.2; 95% CI, 1.0–1.4) and extra-intestinal cancers 
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(SIR, 1.3; 95% CI, 1.2–1.4), with the strongest associations for hematological malignancies (SIR, 
1.9; 95% CI, 1.5–2.3), smoking-related cancers (SIR 1.5, 95% CI 1.3–1.8), and melanoma (SIR, 
1.4; 95% CI, 1.0–1.9). Associations between UC and gastrointestinal and extra-intestinal cancers 
were weaker (SIR, 1.1; 95% CI, 1.0–1.2 and SIR, 1.1; 95% CI, 1.0–1.1, respectively). The relative 
risk of extra-intestinal cancers among patients with IBD was relatively stable over time, although 
the risk of gastrointestinal cancers decreased.
Conclusions—Patients with IBD, particularly CD, are at increased risk for gastrointestinal and 
extra-intestinal malignancies. The relative risk of gastrointestinal malignancy has deceased since 
1978, without a concomitant increase in the risk of non-gastrointestinal malignancy.
Keywords
Epidemiology; Crohn’s disease; ulcerative colitis; colorectal cancer; GI tumor
INTRODUCTION
Gastrointestinal cancers are widely acknowledged as a long-term complication of 
inflammatory bowel diseases, likely as a result of chronic inflammation. Therefore, it is 
possible the medical therapy that decreases intestinal inflammation might protect against 
gastrointestinal malignancy. A recently published population based study in Denmark 
demonstrated a decreasing risk of colorectal cancer over the past 3 decades, providing some 
support for this hypothesis.1 However, a North American study yielded conflicting results, 
demonstrating a stable risk over time, despite increasing use of immunosuppressive and 
biological therapies.2
In addition to gastrointestinal malignancy, patients with IBD may also be at increased risk of 
extra-intestinal malignancy, including lymphoma3–5, non-melanoma skin cancer 
(NMSC)6–9, and melanoma9 among others. A meta-analysis of eight population-based 
cohort studies showed a small increase in the risk of selected extra-intestinal malignancies in 
IBD patients (SIR, 1.10; 95% confidence interval (CI) 0.96–1.27). However, most of the 
studies included data collected prior to the widespread use of immunosuppressive agents and 
biologics10, whose use may affect cancer risk.
If immunosuppressive medications reduce the risk of gastrointestinal malignancy by 
suppressing intestinal inflammation but increase the risk of extra-intestinal malignancies, 
IBD patients may be trading off one set of risks for another. We therefore sought to 
comprehensively evaluate both intestinal and extra-intestinal malignancies, as well as the 
occurrence of any invasive cancer, in a nationwide cohort of patients with IBD in Denmark. 
We also sought to evaluate whether the IBD-associated risks have changed over the last 
three decades.
METHODS
We performed a nationwide, historical cohort study in Denmark to compare the number of 
cancers occurring in patients with a registered diagnosis of CD and UC to the number of 
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cancers expected in the general population, after standardization by sex, age, and calendar 
period (1 year intervals).
Data Sources
The Danish Civil Registration System (DCRS) assigns a personal identifier to each Danish 
resident at the time of birth or immigration, and also monitors the occurrence of death or 
emigration from the country.11 The DCRS thus can provide denominator data for event rates 
in the population. The civil registration number can link individuals throughout the 
numerous registries maintained in Denmark.
The Danish National Patient Register (DNPR) contains records on all acute care hospital 
discharges occurring after January 1, 1977.12 Since 1995, the database has also included 
hospital outpatient visits, accounting for essentially all specialist gastroenterology and 
cancer care in Denmark. Data elements include civil registration number, dates of hospital 
admission and discharge, surgical procedures, and up to 20 discharge diagnoses for each 
hospitalization. All inpatient and outpatient hospital visits are assigned diagnosis codes 
according to the International Classification of Diseases [8th revision, (ICD-8) until the end 
of 1993 and 10th revision (ICD-10) thereafter].
The Danish Cancer Registry (DCR) has prospectively recorded all cases of incident cancers 
diagnosed in Denmark since 1943.13 Cancers diagnosed after January 1, 2004 are classified 
according to ICD-10. Cancers diagnosed previously have been re-coded in this format. 
Comprehensive evaluation has shown that the Registry is 95 to 98 percent complete and 
valid.13
Study population and IBD exposure classification
The source population consisted of all Danish residents during the time period spanning 
January 1, 1978 through December 31, 2010 (n=7,955,034; 171.4 million person-years of 
follow up). We used the DNPR to identify patients with Crohn’s disease (CD) and ulcerative 
colitis (UC). We considered patients with ICD-8 code 563.01 and/or ICD-10 K50 to have 
CD, and patients with ICD-8 code 563.19 and/or ICD-8 code 569.04, and/or ICD-10 K51 to 
have UC. To avoid diagnostic ambiguity, patients with codes for both conditions were 
excluded from all analyses. Prior work has validated the completeness and accuracy of the 
DNPR for identifying patients with IBD14 and other chronic illnesses15. For IBD, a 
validation study compared diagnoses of CD and UC recorded in the database with hospital 
and pathology records and found the sensitivity to be 94% for both CD and UC, and the 
specificity to be 97% for CD and 90% for UC respectively.14
Cancer outcome classification
The following cancer outcomes were identified from the DCR: 1) any invasive malignancy, 
excluding NMSC, 2) gastrointestinal cancers (colorectal, small intestine, and other 
gastrointestinal cancers including those in the esophagus, stomach, liver, gallbladder and 
biliary tract, pancreas, and anal canal), 3) invasive extra-intestinal cancers, and 4) NMSC. 
We also analyzed the following extra-intestinal cancer groupings: a) hematological 
malignancies (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphoid leukemia, 
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myeloid leukemia, and monocytic leukemia) because of their prior associations with 
immunosuppressive medication use3–5; b) female reproductive cancers (breast, ovary, and 
uterus) because emerging data suggests that female sexual hormones, including oral 
contraceptives and hormone replacement therapies, may increase the risk of IBD itself16, 17; 
and c) smoking-related cancers (lung, larynx, oral cavity & pharynx, bladder, kidney, and 
ureter) because of the well described associations between tobacco use and IBD risk.18 
Additionally, we separately analyzed selected other common malignancies including 
prostate, lung, bladder, melanoma, breast, and uterus19.
Cancers occurring within one year of a registered diagnosis of IBD may be due to a number 
of factors including: 1) First recording of prevalent IBD in the DNPR at the time health care 
was sought for cancer, 2) Increased detection of cancer following IBD diagnosis due to 
increased health care contact/detection, 3) Co-diagnosis of IBD and cancer simultaneously 
due to overlapping symptoms and diagnostic procedures, and 4) Misclassification of IBD or 
cancer. Therefore, our main analyses focus on cancers occurring one or more years 
following the date that the diagnosis of CD or UC was first recorded in the Patient Registry, 
consistent with the approach taken by others.1
Analysis
We constructed cohorts of CD and UC patients who had not had a recorded diagnosis of 
invasive cancer prior to their first registered diagnosis of CD or UC. Each patient was 
followed from the first recorded IBD diagnosis until first occurrence of invasive cancer, 
death, emigration, or end of the study period. For cancer types occurring in ≥ 5 patients, 
standardized incidence ratios (SIRs) were used to compare the observed number of cancers 
to the expected number, calculated on the basis of national incidence rates obtained from the 
DCR according to sex, age, and calendar period in one-year intervals. Multiplying the 
number of person-years of observation by the incidence rates yielded the number of cancer 
cases that would be expected if patients with IBD had the same risk of cancer as the general 
population.
Confidence intervals were computed based on the assumption that the observed number of 
cases follows a Poisson distribution. Exact limits were used when the observed number was 
less than 10; otherwise, Byar’s approximation was used.20 All analyses were stratified by 
time from first recorded IBD diagnosis until cancer (<1 year or ≥1 year). We also stratified 
by calendar year of cancer diagnosis (1978–1987, 1988–1997, and 1998–2010), age at IBD 
diagnosis (0–19 years, 20–39 years, and ≥40 years), age at cancer diagnosis (0–29 years, 
30–49 years, 50–69 years, and ≥ 70 years) and gender. For analyses of colorectal cancer, 
liver cancer, and gallbladder cancer, SIRs were stratified by the presence of a registered 
diagnosis of cholangitis (ICD-8 code 57504 and ICD-10 code K83.0) recorded prior to 
cancer diagnosis. We also performed an additional analysis of colorectal cancers occurring 
in the most recent time period (1998 to 2010), censoring individuals with UC at the time of 
colectomy (codes 45060, 45061, 45080, and 45081 from 1978–1995, and codes KJFH 
thereafter). Finally, in addition to analyzing relative risk, we also calculated the absolute risk 
of cancers occurring 1–11 years following IBD diagnosis.
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All statistical analyses were performed using SAS version 9.2 (Cary, NC). The study 
protocol was approved by the Danish Protection Agency (record number 1-16-02-1-08), and 
granted exemption from review by the Institutional Review Board at the University of North 
Carolina at Chapel Hill because it involved use of existing, de-identified data.
RESULTS
Cohort Composition and Overall Cancer Risk
We identified 13,756 individuals with a registered diagnosis of CD (mean age 40.6 years, 
median age 36.5 years) and 35,152 individuals with UC (mean age 46.5 years, median age 
44.2 years) who were followed for a mean of 7.6 and 7.8 years respectively. We excluded 
6,191 individuals with diagnoses for both conditions. Among patients with CD, 208 cases of 
invasive cancer occurred within the first year of diagnosis (SIR = 3.6, 95% CI: 3.1–4.1) and 
772 cases in second and subsequent years (SIR = 1.3, 95% CI: 1.2–1.4). Among UC 
patients, 376 cases of invasive cancer occurred within 1 year (SIR = 1.8, 95% CI: 1.6–2.0) 
and 2331 cases in second and subsequent years (SIR = 1.1, 95% CI: 1.0–1.1) (Table 1).
Gastrointestinal Cancers
After the first year following diagnosis, UC and CD were weakly associated with 
gastrointestinal cancers overall (SIR 1.1, 95% CI: 1.0 to 1.2 and SIR 1.2, 95% CI: 1.0–1.4 
respectively). Associations with specific gastrointestinal cancers are shown in Table 1 and 
Supplemental Table 1. No associations with colorectal cancer were observed for either CD 
or UC. A subanalysis of colorectal cancer occurring in UC patients between 1998 and 2010 
which censored follow-up at the time of colectomy also showed no excess risk (SIR 1.0, 
95% CI: 0.9–1.2). However, among UC patients with a recorded diagnosis of cholangitis, 
the risk of colorectal cancer was significantly increased (SIR 8.6, 95% CI 3.9–16.3). CD was 
associated with a significantly increased risk of cancers of the small intestine (SIR 8.4, 95% 
CI: 4.3–14.7) and gallbladder and biliary tract (SIR 2.4, 95% CI 1.1–4.5). For UC, there 
were notable associations for cancers of the liver (SIR 1.6, 95% CI 1.1–2.2), and gallbladder 
(SIR 2.5, 95% CI 1.8–3.5). The SIRs for liver and gallbladder cancer in patients with UC 
and cholangitis were 80.0 (95% CI: 32.1–164.8) and 129.1 (95% CI: 47.4–281.5) 
respectively, whereas in patients without cholangitis the SIRs were 1.3 (95% CI 0.9–1.9) 
and 2.1 (1.4–3.0) respectively.
The absolute risks of selected gastrointestinal cancers are shown in Table 2 and Figure 1. 
Overall, the absolute risk of gastrointestinal cancers 1–11 years following diagnosis of CD 
was 1.2 percent (95% CI: 1.0–1.4). For UC, the overall absolute risk was 1.4 percent (95% 
CI 1.2–1.6). Approximately 50% of gastrointestinal cancers in both CD and UC patients 
occurred in the colorectum.
Extra-intestinal Cancers
The risk of extra-intestinal cancers was increased for patients with CD (SIR 1.3, 95% CI 
1.2–1.4), and to a minimal extent for UC (SIR 1.1 (95% CI 1.0–1.1). In CD, this was largely 
due to an increased risk of hematological malignancies (SIR 1.9, 95% CI 1.5–2.3), smoking-
related cancers (SIR 1.5, 95% CI 1.3–1.8), and melanoma (SIR 1.4, 95% CI 1.0–1.9). 
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Neither CD nor UC were associated with a risk of female reproductive cancers. UC, but not 
CD, was associated with a statistically significant increase in prostate cancer, though the 
association was relatively weak (SIR 1.2, 95% CI 1.1–1.4). In separate analyses, both CD 
and UC were associated with an increased risk of non-melanoma skin cancer (SIR for CD 
2.1, 95% CI 1.8–2.3 and SIR for UC 1.8, 95% CI 1.7–2.0).
For both CD and UC, the absolute risks of extra-intestinal cancers, excluding NMSC, were 
far greater than that of intestinal cancers (Table 2 and Figure 1). For CD, the overall 
absolute risk of extra-intestinal cancers, excluding NMSC, 1–11 years following diagnosis 
was 4.4 percent (95% CI: 4.0–4.9). For UC, the absolute risk was slightly higher at 5.0 
percent (95% CI 4.7–5.3), likely related to the older age of these patients in comparison to 
those with CD. However, the absolute risk of hematological malignancies was higher among 
CD patients than UC patients (0.7 percent versus 0.4 percent).
Effect of Age of IBD Diagnosis
For both CD and UC, the relative risk of invasive cancer one or more years after IBD 
diagnosis was highest for those diagnosed with IBD before 20 years of age (SIR for CD 2.3, 
95% CI 1.5–3.4 and SIR for UC 2.0, 95% CI 1.4–1.7) (Table 3). This was largely due to the 
risk of gastrointestinal cancers (SIR for CD 7.3, 95% CI 2.0–18.6 and SIR for UC 20.2, 95% 
CI 13.1–29.8).
Cancers Occurring Early in Life
The relative risk of cancer occurring early in life, particularly gastrointestinal cancer, was 
markedly elevated in UC patients (SIR for gastrointestinal cancer diagnosed before 30 years 
of age 15.8, 95% CI 7.3–30.1). The relative risk of early-life cancers also appears to be 
increased in CD, though more modestly (SIR for invasive cancer diagnosed before 30 years 
of age 1.8, 95% CI 1.1–2.7). More detailed analyses of cancer types occurring early in life 
were limited by sparse data.
Cancer Relative Risk over Time
The relative risk of gastrointestinal cancers among patients with CD and UC has decreased 
over the last 3 decades (Table 3). Between 1978–1987, the SIR of gastrointestinal cancers in 
patients with CD was 1.9 (95% CI 1.0–3.4). In the last two decades, the relative risk of 
gastrointestinal cancers among patients with CD did not differ from the general population. 
Similarly the SIR of gastrointestinal cancers in UC patients has decreased from 1.4 during 
1979–1987 to 1.1 in the last two decades. Over this same period, the relative risk for extra-
intestinal cancers and hematological malignancies has remained largely unchanged.
DISCUSSION
In this population-based nationwide study, we found that patients with CD and UC have a 
30% and 10% higher long term risk of invasive cancer than the general population. The 
excess risk in CD patients is largely due to extra-intestinal cancers, particularly 
hematological malignancies and melanoma, both of which may be related to immune 
suppression, and smoking-related cancers. With regards to gastrointestinal malignancies, CD 
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was associated with a higher risk of cancer of the small intestine, and both CD and UC were 
associated with an increased risk of hepatobiliary malignancies, particularly in patients with 
cholangitis.
The absolute risk of invasive malignancy was somewhat higher in the UC cohort, as 
compared to the CD cohort, likely related to older age: 6.3% during the 1–11 years after 
diagnosis versus 5.6%. The absolute risk of hematological malignancies was nearly twice 
that in CD patients versus those with UC, though, this risk was lower than that of 
gastrointestinal malignancies as displayed in Figure 1.
Our findings of declining gastrointestinal cancer risk over time, particularly colorectal 
cancer, are consistent with the results of some, but not all, studies from Denmark, Western 
Europe, and North America. Ekbom et al demonstrated a markedly increased risk of CRC in 
UC patients, based on follow-up data from 1922 to 1984.21 More recently two studies from 
Denmark have shown minimal or no increase in the relative risk of CRC in patients with 
IBD,1, 22 during a period when the population rates have slightly increased23. However, a 
study in North America (where colorectal cancer rates have been falling23) failed to confirm 
this trend towards a lesser excess risk of colorectal cancer in patients with IBD.2 The 
declining excess risk of gastrointestinal malignancy among IBD patients in Denmark among 
may be due to earlier and more frequent use of immunosuppressive agents and biologics 
which may more effectively control inflammation, or other factors such as aminosalicylate 
use or more frequent colonoscopy and surgery in patients with UC.
Importantly, this study provides reassuring data that the declining risk for gastrointestinal 
malignancy observed here and in other recent Danish studies1, 22 has not been offset by a 
concomitant increase in the risk of extra-intestinal or hematological malignancies. These 
findings suggest that changes in the medical and surgical treatment of IBD and/or other 
secular trends have not substantially impacted cancer relative risk on a population basis.
In regards to extra-intestinal malignancy, we found an increased risk of smoking-related 
malignancies in patients with CD but not UC, consistent with prior literature.10 This is also 
consistent with the epidemiology of IBD, as smoking is a well-known risk factor for CD and 
protective factor for UC. As in prior studies, we have noted higher risks of melanoma in CD 
and NMSC in patients with both CD and UC.6–9 Taken together, these findings suggest 
preventive measures, including smoking cessation and routine skin examinations, may 
mitigate some of the excess cancer burden among IBD patients, particularly those with CD.
Despite suggestions from a few studies that female sexual hormones may increase the risk of 
IBD16, 17, we found no association between IBD and female reproductive cancers. Our 
findings indicate an increased risk of hematological malignancies in patients with CD, but 
not UC, a pattern that has been previously reported among IBD patients treated with 
immunosuppressive medications.3, 5 Prior population-based studies and a recent meta-
analysis did not demonstrate a significantly increased risk of lymphoma in the IBD 
population, though these prior studies were underpowered.10, 24
Another noteworthy finding in this study is that relative risk of cancer in individuals 
diagnosed with IBD prior to 20 years of age is nearly twice that of individuals whose initial 
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IBD diagnosis was recorded after 40 years of age. This is largely due to the risk of 
gastrointestinal cancers, in both CD and UC, as has been previously described.1 However, in 
CD, the risk of extra-intestinal cancers also appears to be increased in those diagnosed with 
IBD at younger ages. We also found that patients with CD and UC were at higher risk of 
cancers occurring earlier in life, reinforcing the importance of initiating proper surveillance 
early in the course of disease.
The strengths of our study include its nationwide, population-based design, which ensures 
complete follow-up and virtually eliminates selection bias. Additionally, the large sample 
size and long study period spanning more than three decades allowed us to calculate distinct 
estimates of cancer risk for a number of different cancer types in patients with CD and UC, 
as well as to stratify these estimates by gender, age at IBD diagnosis, year of cancer 
diagnosis, age at cancer diagnosis, and time from IBD diagnosis. We used previously 
validated definitions of both the exposures14 and outcomes13 of interest, minimizing any 
misclassification.
Although our study was large, we did not have enough subjects to compute age-and sex-
specific estimates of absolute cancer risks. The risks reported reflect an average over all 
subjects and sexes, and do not apply well to the youngest and oldest ages. Other limitations 
include the possibility of detection bias, i.e. detection of subclinical events more often in 
IBD patients than the general population due to more rigorous medical follow-up. This may 
partially explain the higher risk of gastrointestinal malignancy in the 1 year period following 
the first recorded IBD diagnosis, as well as less severe cancers such as NMSC. However, 
most of the cancers analyzed in this study would eventually have come to clinical attention 
and been included in the overall analysis, regardless of IBD status. Furthermore, the 
declining excess risk of gastrointestinal malignancy over time argues against significant 
detection bias. Another potential limitation is left censoring of the date of diagnosis of IBD. 
Individuals who presented clinically before 1978 or diagnosed as an outpatient before 1995 
would have developed disease prior to the first recorded diagnosis. This would limit our 
ability to fully evaluate absolute risk as function of time of diagnosis and the association 
between age at IBD diagnosis and cancer risk. Finally, exclusion of patients with very mild 
disease and no inpatient encounters prior to 1995 may have led to an overestimation of 
gastrointestinal cancer risk, thereby accounting for some of the observed decreasing risk in 
later years. However, this extent of this bias should be minimal given that the Patient 
Registry included nearly all IBD patients (94%) prior to the inclusion of outpatient visits in 
1995.14
In summary, patients with CD and UC are at increased risk of both intestinal and extra-
intestinal malignancies. The differing risk of specific cancers between CD and UC may 
reflect the underlying disease states, and/or lifestyle factors. The risk of gastrointestinal 
malignancy appears to be decreasing in recent years without a substantial increase in the 
overall risk of malignancy, which may suggest that the benefits of current management 
paradigms outweigh the cancer-related risks.
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Table 2
Absolute Risk of Selected Cancers occurring 1–11 years following a diagnosis of Inflammatory Bowel 
Diseases (IBD), Denmark, 1978–2010
Crohn’s disease (n=13,756)
Absolute risk percent (95%CI)
Ulcerative colitis (n=35,152)
Absolute risk percent (95%CI)
Any invasive cancer 5.6 (5.1–6.1) 6.3 (6.0–6.6)
Any gastrointestinal cancer 1.2 ((1.0–1.4) 1.4 (1.2–1.6)
Colorectal cancer 0.6 (0.4–0.8) 0.8 (0.7–0.9)
Small intestine cancer 0.07 (0.03–0.15) 0.03 (0.01–0.06)
Other GI cancers 0.5 (0.4–0.7) 0.6 (0.5–0.7)
Any extra-intestinal cancer 4.4 (4.0–4.9) 5.0 (4.7–5.3)
Hematological malignancies 0.7 (0.5–0.9) 0.4 (0.3–0.5)
Smoking related cancers 1.3 (1.1–1.5) 1.3 (1.2–1.5)
Female reproductive cancers 0.9 (0.7–1.1) 1 2 (1.1–1.3)
Other common cancer sites
Prostate 0.4 (0.3–0.5) 0.7 (0.6–0.8)
Lung 0.9 (0.7–1.1) 0.8 (0.7–1.0)
Bladder 0.2 (0.1–0.3) 0.4 (0.3–0.4)
Melanoma 0.3 (0.2–0.5) 0.3 (0.2–0.4)
Breast 0.8 (0.6–1.0) 1.0 (0.8–1.1)
Uterus 0.07 (0.03–0.14) 0.1 (0.1–0.2)
Non-melanoma skin cancer 2.2 (1.9–2.5) 3.1 (2.9–3.3)
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